Medical-cannabis producer Tilray is collaborating with McMaster University in Hamilton, Ontario to study CBD as effective medicine to treat anxiety disorders, including General Anxiety Disorder and Panic Disorder.
The relationship between inflammation, anxiety and CBD treatment will also be studied.
The clinical trial is expected to take approximately two years to complete and make a significant contribution to enhancing current understanding of the effects of cannabis in anxiety disorders.
The study will be led by psychiatry professor Michael Van Ameringen, MD, FRCPC.
Dr. Van Ameringen is a widely published psychiatry specialist in patients with anxiety disorders who also suffer from mood disorders (e.g. bipolar) and/or OCD.
He serves on the board of the Anxiety and Depression Association of America and is on the editorial board for the journal Depression and Anxiety.
The phase three clinical trial is recruiting approximately 50 individuals between 21 and 65 years of age.
Participants will receive up to 800 mg/day of Tilray’s CBD oil capsules.